A study published in The New England Journal of Medicine shows that Bepirovirsen significantly increases the likelihood of achieving a functional cure for chronic hepatitis B.
Fatty liver and hepatitis B can coexist and worsen liver damage. Combined treatment helps reduce inflammation, fibrosis, and disease progression.
A study suggests GST-HG141 may become an effective new hepatitis B treatment for patients with incomplete response to current antiviral therapies.
Hydronidone has demonstrated significant reversal of liver fibrosis in patients with chronic hepatitis B, offering a potential new therapeutic option.
Hepalatide, used with pegylated interferon-alpha, shows promise for curing chronic hepatitis B by eliminating cccDNA from liver cells, according to early study results presented in a European liver congress.
A new treatment for chronic hepatitis B using an antisense probe shows promising results, with 62% achieving theoretical cure and mild side effects.
Chronic hepatitis B affects over 250 million people worldwide and can progress to cirrhosis and liver cancer.
Fatty liver is one of the most frequent diseases and affects 25-30% of the world population.
Chronic hepatitis B virus infection is a global health problem.
New trials published with hepatitis B patients suggests the use of liposome nanoparticles with virus antigens for their treatment.